ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has completed the previously announced acquisition of Aptiv Solutions.

Aptiv Solutions is a recognised leader in the design and execution of adaptive clinical trials for pharmaceutical and biotech customers. The company also has in-depth experience in the management of medical device trials and its Japanese subsidiary, Niphix, is a full-service, oncology-focused CRO serving both Japanese and international customers.

“Aptiv’s adaptive trial capabilities, combined with our existing technology platforms, such as ICONIK and Firecrest, will further differentiate our services and help our customers take time and cost out of the development process,” commented Dr. Nuala Murphy, president, ICON Clinical Research Services. “Their presence in Japan and medical device capabilities will also broaden our offerings in these markets.”